retatrutide triple agonist gip glp-1 glucagon Eli Lilly just announced striking Phase 3 results for retatrutide, an experimental “triple agonist” that acts on three gut-hormone targets at once. On the top dose, people lost an average of 28% New obesity drugs are coming,

Because peptides are naturally occurring in the body and in food, they are unlikely to cause serious side effects in healthy people as long as they are taking in reasonable amounts

We used our branded citrus-garlic sauces, slow braising, proper searing and seasoning precision so guests feel satisfied even with a smaller volume of food. The menu includes Gabe Caliendo, co-founder and VP of R&D at Lazy Dog Restaurant & Bar, took similar steps in creating the Protein Crunch Bowl, part of the brands new Mindful Meals menu

Mutant variants were then generated by site-directed mutagenesis and all mutants were fully sequenced

And current data reiterates the potential benefits of GLP-1 drugs for weight loss, with a recent study finding that medications like Wegovy that are prescribed for weight loss may reduce the risk of heart attack, stroke or heart-related death in people with cardiovascular disease